Idera Taps Abbott to Develop CDx for B-Cell Lymphoma Drug Candidate | GenomeWeb

NEW YORK (GenomeWeb) — Idera Pharmaceuticals said today that it has entered into an agreement with Abbott to develop an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with its lead drug candidate IMO-8400.

Under the agreement, Abbott will develop a test using PCR technology to identify the presence of the MYD88 L265P oncogenic mutation in tumor biopsy samples with high sensitivity and specificity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.